A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This is a single-center, randomized, single-blind, placebo-controlled, ascending single oral dose study designed to evaluate the safety, tolerability, and pharmacokinetic (PK) profiles of SEP-363856 and its metabolite SEP-363854 in male and female subjects with schizophrenia.
Epistemonikos ID: 44b4e05a64cc6c67db3ae09751cbdec537f21613
First added on: May 11, 2024